Anti-Parkinson's disease drugs and pharmacogenetic considerations.

Agúndez, José A G

Anti-Parkinson's disease drugs and pharmacogenetic considerations. [electronic resource] - Expert opinion on drug metabolism & toxicology Jul 2013 - 859-74 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review

1744-7607

10.1517/17425255.2013.789018 doi


Aryl Hydrocarbon Hydroxylases--genetics
Benzothiazoles--therapeutic use
Benztropine--therapeutic use
Bromocriptine--therapeutic use
Cabergoline
Catechols--therapeutic use
Cytochrome P-450 CYP1A2--metabolism
Cytochrome P-450 CYP1A2 Inhibitors
Cytochrome P-450 CYP2B6
Cytochrome P-450 CYP2C19
Cytochrome P-450 CYP3A--genetics
Ergolines--therapeutic use
Genetic Markers
Humans
Indans--therapeutic use
Indoles--therapeutic use
Levodopa--therapeutic use
Lisuride--therapeutic use
Nitriles--therapeutic use
Parkinson Disease--drug therapy
Pergolide--therapeutic use
Pharmacogenetics
Pramipexole
Receptors, Dopamine D2--genetics
Receptors, Dopamine D3--genetics
Reproducibility of Results
Selegiline--therapeutic use